Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique

被引：7

作者：

Bastard, Mathieu ^{[1
]}

Molfino, Lucas ^{[2
]}

Mutaquiha, Claudia ^{[3
]}

Galindo, Miriam Arago ^{[2
]}

Zindoga, Pereira ^{[3
]}

Vaz, Deise ^{[2
]}

Mahinca, Ivan ^{[3
]}

DuCros, Philipp ^{[4
]}

Rusch, Barbara ^{[5
]}

Telnov, Alex ^{[5
]}

机构：

[1] Epictr, 8 Rue St Sabin, F-75011 Paris, France

[2] Med Sans Frontieres, Maputo, Mozambique

[3] Minis Hlth, Maputo, Mozambique

[4] Burnet Inst, Melbourne, Australia

[5] Med Sans Frontieres, Geneva, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 10期

关键词：

multidrug-resistant tuberculosis; short regimen; bedaquiline; treatment outcomes; injectable drugs;

D O I：

10.1093/cid/ciz196

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.

引用

页码：1809 / 1811

页数：3

共 50 条

[1] Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
Mase, Sundari
Chorba, Terence
Parks, Samuel
Belanger, Ann
Dworkin, Felicia
Seaworth, Barbara
Warkentin, Jon
Barry, Pennan
Shah, Neha
CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) : 1010 - 1016
[2] Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
Lee, Hoon Hee
Jo, Kyung-Wook
Yim, Jae-Joon
Jeon, Doosoo
Kang, Hyungseok
Shim, Tae Sun
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 98 : 478 - 485
[3] Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging
Li, Yang
Sun, Feng
Zhang, Wenhong
DRUG DEVELOPMENT RESEARCH, 2019, 80 (01) : 98 - 105
[4] Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis
Worley, Marylee V.
Estrada, Sandy J.
PHARMACOTHERAPY, 2014, 34 (11): : 1187 - 1197
[5] Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
Pecora, Francesco
Dal Canto, Giulia
Veronese, Piero
Esposito, Susanna
MICROORGANISMS, 2021, 9 (05)
[6] Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis
Martin-Garcia, Marta
Esteban, Jaime
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (05) : 535 - 541
[7] Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
Yao, Ge
Zhu, Muxin
Nie, Qi
Chen, Nanshan
Tu, Shengjin
Zhou, Yong
Xiao, Fan
Liu, Yuan
Li, Xi
Chen, Hua
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (01)
[8] BEDAQUILINE FOR THE TREATMENT OF PULMONARY, MULTIDRUG-RESISTANT TUBERCULOSIS IN ADULTS
Gras, J.
DRUGS OF TODAY, 2013, 49 (06) : 353 - 361
[9] Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea
Kang, Hyungseok
Jo, Kyung-Wook
Jeon, Doosoo
Yim, Jae-Joon
Shim, Tae Sun
RESPIRATORY MEDICINE, 2020, 167
[10] Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis
Nagabushan, H.
Roopadevi, H. S.
JOURNAL OF POSTGRADUATE MEDICINE, 2014, 60 (03) : 300 - 302

← 1 2 3 4 5 →